Approved for use through 07/31/2006, ONS

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB cont

	Application Number			
	Filing Date			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Paul		I R. HARVEY	
Not for submission under 37 CFR 1.99)	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	PHNI 040110US	Π

U.S.PATENTS							Remove	
Examiner Initial*	niner Cite Patent Number Kind Issue Date Name of Patentee or Applicant		Releva	Columns,Lines where nt Passages or Relevant s Appear				
	1	5311131		1994-05-10	Smith	all		
2 5758646 1998-06-02 Van der Moulen, et al.		all						
	3	6108573		2000-08-22	00-08-22 Debblins, et al. all			
	4	6484048		2002-11-19	Hoshino, et al.	all		
If you wis	h to a	dd additional U.S. Pater			ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Cite Publication Number Rind Publication Name of Patentee or Applicant Relev		Releva	Columns,Lines where nt Passages or Relevant Appear					
	1	20020173715	A1	2002-11-21	Kruger, et al.	all		
	2	20030011369	A1	2003-01-16	Brittain, et al.	all		
If you wisi	h to a	l dd additional U.S. Publis	hed Ap	l plication citation	I n information please click the Ad-	d button	Add	
				FOREIGN PAT	TENT DOCUMENTS		Remove	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Examiner Cite Foreign Document

Initial* No Number3

Application Number		
Filing Date		
First Named Inventor Paul		R. HARVEY
Art Unit		
Examiner Name		
Attorney Docket Number		PHNL040110US

Name of Patentee or

Applicant of cited

Pages, Columns, Lines

where Relevant

Passanes or Rel

	mou	110	Trumber-	0000-1		Dunc	Document	Figures Appear	
		1	EP 1 220 153	EP	A2	2002-07-03	GE Medical	all	
		2	EP 1 221 623	EP	A2	2002-07-10	GE Medical	all	
		3	EP 1 362 550	EP	A1	2003-11-19	GE Medical	all	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
I	NON-PATENT LITERATURE DOCUMENTS Remove								
	Examiner Cite Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, div and/or country where published.							Ţ5	

Kind Publication

Date

Country

If you wish to add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE

Examiner Signature Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Application Number Fling Date Fling Date Fling Date Fling Date Fling Number Paul R HARVEY Art Unit Examiner Name Attorney Oochet Number PHNL040110US

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sec 37 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) in the control of the control

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-08-28
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, u.S. Operationed for Commence, P. 0. Bot 1450, Alexandria, V.3.231.14450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via self or in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.